Lipopolysaccharide precipitates hepatic encephalopathy and increases blood-brain barrier permeability in mice with acute liver failure

Liver International

Volumn 34, Issue 3, 2014, Pages 353-361

  Chastre, Anne ^a   Bélanger, Mireille ^a   Nguyen, Bich N ^a   Butterworth, Roger F ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Acute liver failure; Azoxymethane; Blood brain barrier; Endotoxemia; Immunoglobulin G extravasation; Lipopolysaccharide; Matrix metalloproteinase 9; Pro inflammatory cytokines; Systemic inflammatory response

Indexed keywords

25 KDA PROTEIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZOXYMETHANE; ENDOTOXIN; GELATINASE B; IMMUNOGLOBULIN G; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AMINOTRANSFERASE; AMMONIA; CYTOKINE; MMP9 PROTEIN, MOUSE;

ACUTE LIVER FAILURE; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; CORNEA REFLEX; DISEASE ACTIVITY; ENDOTOXEMIA; EXTRAVASATION; HEPATIC COMA; HEPATIC ENCEPHALOPATHY; HYPERAMMONEMIA; LIVER TOXICITY; MALE; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; UPREGULATION; ANIMAL; BLOOD; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; INFLAMMATION; LIVER; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PERMEABILITY;

AMMONIA; ANIMALS; AZOXYMETHANE; BLOOD-BRAIN BARRIER; CYTOKINES; DISEASE MODELS, ANIMAL; HEPATIC ENCEPHALOPATHY; INFLAMMATION; LIPOPOLYSACCHARIDES; LIVER; LIVER FAILURE, ACUTE; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; PERMEABILITY; TRANSAMINASES;

EID: 84893716063     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12252     Document Type: Article

References (42)

1. Rolando N, Wade J, Davalos M, et al. The systemic inflammatory response syndrome in acute liver failure. Hepatology 2000; 32: 734-9.
2. Vaquero J, Polson J, Chung C, et al. Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology 2003; 125: 755-64.
3. Iwai H, Nagaki M, Naito T, et al. Removal of endotoxin and cytokines by plasma exchange in patients with acute hepatic failure. Crit Care Med 1998; 26: 873-6.
4. Galanos C, Freudenberg MA, Reutter W. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci USA 1979; 76: 5939-43.
5. Takada Y, Ishiguro S, Fukunaga K, et al. Increased intracranial pressure in a porcine model of fulminant hepatic failure using amatoxin and endotoxin. J Hepatol 2001; 34: 825-31.
6. Belanger M, Cote J, Butterworth RF. Neurobiological characterization of an azoxymethane mouse model of acute liver failure. Neurochem Int 2006; 48: 434-40.
7. Shimojima N, Eckman CB, McKinney M, et al. Altered expression of zonula occludens-2 precedes increased blood-brain barrier permeability in a murine model of fulminant hepatic failure. J Invest Surg 2008; 21: 101-8.
8. Wispelwey B, Lesse AJ, Hansen EJ, Scheld WM. Haemophilus influenzae lipopolysaccharide-induced blood brain barrier permeability during experimental meningitis in the rat. J Clin Invest 1988; 82: 1339-46.
9. Moor AC, de Vries HE, de Boer AG, Breimer DD. The blood-brain barrier and multiple sclerosis. Biochem Pharmacol 1994; 47: 1717-24.
10. de Vries HE, Blom-Roosemalen MC, van Oosten M, et al. The influence of cytokines on the integrity of the blood-brain barrier in vitro. J Neuroimmunol 1996; 64: 37-43.
11. Nguyen JH, Yamamoto S, Steers J, et al. Matrix metalloproteinase-9 contributes to brain extravasation and edema in fulminant hepatic failure mice. J Hepatol 2006; 44: 1105-14.
12. Warren HS. Editorial: mouse models to study sepsis syndrome in humans. J Leukoc Biol 2009; 86: 199-201.
13. Beauchesne E, Desjardins P, Butterworth RF, Hazell AS. Up-regulation of caveolin-1 and blood-brain barrier breakdown are attenuated by N-acetylcysteine in thiamine deficiency. Neurochem Int 2010; 57: 830-7.
14. Bemeur C, Qu H, Desjardins P, Butterworth RF. IL-1 or TNF receptor gene deletion delays onset of encephalopathy and attenuates brain edema in experimental acute liver failure. Neurochem Int 2010; 56: 213-5.
15. Bemeur C, Vaquero J, Desjardins P, Butterworth RF. N-acetylcysteine attenuates cerebral complications of non-acetaminophen-induced acute liver failure in mice: antioxidant and anti-inflammatory mechanisms. Metab Brain Dis 2010; 25: 241-9.
16. Rangroo TV, Thrane AS, Chanag J, et al. Real-time analysis of microglial activation and motility in hepatic and hyperammonemic encephalopathy. Neuroscience 2012; 220: 247-55.
17. Matkowskyj KA, Marrero JA, Carroll RE, et al. Azoxymethane-induced fulminant hepatic failure in C57BL/6J mice: characterization of a new animal model. Am J Physiol 1999; 277: G455-62.
18. Bernal W, Donaldson P, Underhill J, Wendon J, Williams R. Tumor necrosis factor genomic polymorphism and outcome of acetaminophen (paracetamol)-induced acute liver failure. J Hepatol 1998; 29: 53-9.
19. Streetz K, Leifeld L, Grundmann D, et al. Tumor necrosis factor alpha in the pathogenesis of human and murine fulminant hepatic failure. Gastroenterology 2000; 119: 446-60.
20. Bemeur C, Butterworth R F. Liver-brain proinflammatory signalling in acute liver failure: Role in the pathogenesis of hepatic encephalopathy and brain edema. Metab Brain Dis 2013; 28: 145-50.
21. Jalan R, Pollok A, Shah SH, Madhavan K, Simpson KJ. Liver derived pro-inflammatory cytokines may be important in producing intracranial hypertension in acute liver failure. J Hepatol 2002; 37: 536-8.
22. Tsuchiya N, Tokushige K, Yamaguchi N, et al. Influence of TNF gene polymorphism in patients with acute and fulminant hepatitis. J Gastroenterol 2004; 39: 859-66.
23. Chastre A, Belanger M, Beauchesne E, et al. Inflammatory cascades driven by tumor necrosis factor-alpha play a major role in the progression of acute liver failure and its neurological complications. PLoS ONE 2012; 7: e49670.
24. Blei AT, Larsen FS. Pathophysiology of cerebral edema in fulminant hepatic failure. J Hepatol 1999; 31: 771-6.
25. Kato M, Hughes RD, Keays RT, Williams R. Electron microscopic study of brain capillaries in cerebral edema from fulminant hepatic failure. Hepatology 1992; 15: 1060-6.
26. Gove CD, Hughes RD, Ede RJ, Williams R. Regional cerebral edema and chloride space in galactosamine-induced liver failure in rats. Hepatology 1997; 25: 295-301.
27. Traber PG, Dal Canto M, Ganger DR, Blei AT. Electron microscopic evaluation of brain edema in rabbits with galactosamine-induced fulminant hepatic failure: ultrastructure and integrity of the blood-brain barrier. Hepatology 1987; 7: 1272-7.
28. Bemeur C, Chastre A, Desjardins P, Butterworth RF. No changes in expression of tight junction proteins or blood-brain barrier permeability in azoxymethane-induced experimental acute liver failure. Neurochem Int 2010; 56: 3.
29. Clemmesen JO, Larsen FS, Kondrup J, Hansen BA, Ott P. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology 1999; 29: 648-53.
30. Tofteng F, Hauerberg J, Hansen BA, et al. Persistent arterial hyperammonemia increases the concentration of glutamine and alanine in the brain and correlates with intracranial pressure in patients with fulminant hepatic failure. J Cereb Blood Flow Metab 2006; 26: 21-7.
31. Duchini A, Govindarajan S, Santucci M, Zampi G, Hofman FM. Effects of tumor necrosis factor-alpha and interleukin-6 on fluid-phase permeability and ammonia diffusion in CNS-derived endothelial cells. J Investig Med 1996; 44: 474-82.
32. Lai JC, Cooper AJ. Brain alpha-ketoglutarate dehydrogenase complex: kinetic properties, regional distribution, and effects of inhibitors. J Neurochem 1986; 47: 1376-86.
33. Zwingmann C, Chatauret N, Leibfritz D, Butterworth RF. Selective increase of brain lactate synthesis in experimental acute liver failure: results of a [H-C] nuclear magnetic resonance study. Hepatology 2003; 37: 420-8.
34. Andersson AK, Ronnback L, Hansson E. Lactate induces tumour necrosis factor-alpha, interleukin-6 and interleukin-1beta release in microglial- and astroglial-enriched primary cultures. J Neurochem 2005; 93: 1327-33.
35. Sporer B, Koedel U, Paul R, et al. Human immunodeficiency virus type-1 Nef protein induces blood-brain barrier disruption in the rat: role of matrix metalloproteinase-9. J Neuroimmunol 2000; 102: 125-30.
36. Fujimura M, Gasche Y, Morita-Fujimura Y, et al. Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res 1999; 842: 92-100.
37. Rosenberg GA. Matrix metalloproteinases in brain injury. J Neurotrauma 1995; 12: 833-42.
38. Palenzuela L, Mas A, Montaner J, Cordoba J. Matrix metalloproteinase-9 in fulminant hepatic failure. Hepatology 2010; 51: 1475-6; author reply 76.
39. Quagliarello V, Scheld WM. Bacterial meningitis: pathogenesis, pathophysiology, and progress. N Engl J Med 1992; 327: 864-72.
40. Sharief MK, Thompson EJ. In vivo relationship of tumor necrosis factor-alpha to blood-brain barrier damage in patients with active multiple sclerosis. J Neuroimmunol 1992; 38: 27-33.
41. Wright G, Shawcross D, Olde Damink SW, Jalan R. Brain cytokine flux in acute liver failure and its relationship with intracranial hypertension. Metab Brain Dis 2007; 22: 375-88.
42. Jiang W, Desjardins P, Butterworth RF. Cerebral inflammation contributes to encephalopathy and brain edema in acute liver failure: protective effect of minocycline. J Neurochem 2009; 109: 485-93.